CD8A and glioblastoma: For instance, in glioblastoma, the YBX1 inhibitor SU056 disrupts the CHK2-YBX1/YBX3 complex, enhances antigen presentation and CD8+ T cell activity, and, when combined with immune checkpoint blockade (ICB), significantly improves survival in preclinical models, demonstrating the feasibility and potential efficacy of small-molecule targeting of YBX1 (25).